China Prostate Cancer Diagnostics Market Size & Outlook
China prostate cancer diagnostics market, 2018-2030 (US$M)
Related Markets
China prostate cancer diagnostics market highlights
- The China prostate cancer diagnostics market generated a revenue of USD 318.2 million in 2023 and is expected to reach USD 560.4 million by 2030.
- The China market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
- In terms of segment, outpatient facilities was the largest revenue generating end use in 2023.
- Home Care is the most lucrative end use segment registering the fastest growth during the forecast period.
Prostate cancer diagnostics market data book summary
| Market revenue in 2023 | USD 318.2 million |
| Market revenue in 2030 | USD 560.4 million |
| Growth rate | 8.4% (CAGR from 2023 to 2030) |
| Largest segment | Outpatient facilities |
| Fastest growing segment | Home Care |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
| Key market players worldwide | MDxHealth SA, Myriad Genetics Inc, Abbott Laboratories, Roche Holding AG, Bayer AG, Siemens Healthineers AG ADR, OPKO Health Inc, Exact Sciences Corp, Pfizer Inc |
Other key industry trends
- In terms of revenue, China accounted for 4.1% of the global prostate cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China prostate cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 376.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prostate Cancer Diagnostics Market Scope
Prostate Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China prostate cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.65% in 2023. Horizon Databook has segmented the China prostate cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
PSA screening test is supported by China, since it is believed that without PSA screening test, the number of early prostate cancer patients would be triple the reported number in 2012. The overall detection rate of prostate cancer in China’s single study center was 42.8%. With a PSA level of 4 to 10 ng/mL, 22.6% were detected with prostate cancer.
PSA screening holds great importance in the initial phase of prostate cancer as it can contribute to the reduction of mortality rate. It is less likely to lead to excessive treatment in China as is claimed by the U.S. and other Western countries. The harms of prostatitis and late diagnoses outweigh the excessive treatment.
Reasons to subscribe to China prostate cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China prostate cancer diagnostics market databook
-
Our clientele includes a mix of prostate cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China prostate cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into China prostate cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China prostate cancer diagnostics market size, by end use, 2018-2030 (US$M)
China Prostate Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
